Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Gianluca Masi,Lorena Salvatore,L Boni, Fotios Loupakis,Chiara Cremolini,Lorenzo Fornaro,Marta Schirripa,Samanta Cupini,Cecilia Barbara,V Safina,Cristina Granetto,E Fea,Lorenzo Antonuzzo,C Boni,Giacomo Allegrini,S Chiara,D Amoroso,Andrea Bonetti,Alfredo Falcone,Carlotta Antoniotti, I Brunetti, E Pfanner, M Morvillo, R Savi,Marco Merlano, P Curcio, S Violante,Federico Cappuzzo, S Bursi,F Di Costanzo,Elisa Giommoni, M Banzi, R Gnoni,Silvia Fanello, C Sonaglio,Daniela Garbarino, C Valsuani, C Puccetti,Lorenzo Marcucci,Jacopo Giuliani, F Dargenio,M Clerico,Vito Lorusso,Antonio Gambino,Oscar Alabiso, Sergio Crispino, S Biancanelli, A Martignetti,R R Silva,Eva Galizia,Vincenzo Catalano, S Vitello, G Fiorentini,Andrea Ardizzoni

Annals of Oncology（2015）

引用 142|浏览9

暂无评分

摘要

The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study evaluating the continuation or reintroduction of bevacizumab with second-line chemotherapy in mCRC patients progressed to a first-line therapy containing bevacizumab. The primary end point was PFS. Despite some limitations, mainly due to the premature interruption, the study met its primary end point.

查看译文

关键词

metastatic colorectal cancer,bevacizumab,second-line,beyond progression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要